株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の分子診断市場 - 成長、動向、および予測(2019年 - 2024年)

Global Molecular Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 546538
出版日 ページ情報 英文 157 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
世界の分子診断市場 - 成長、動向、および予測(2019年 - 2024年) Global Molecular Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 157 Pages
概要

世界の分子診断市場は、2018年に78億5,445万米ドルとなりました。同市場は、2019年から2024年までの間に9.23%のCAGRで拡大する見通しで、2024年には133億4,035万米ドルまで成長すると予測されています。市場の成長要因には、世界中でのバクテリアおよびウイルス流行の大規模発生、ポイントオブケア診断、薬理ゲノムにおける最近の進歩、および急速に進化する技術などが挙げられます。

当レポートでは世界の分子診断市場について調査しており、市場の動向や機会、成長および阻害要因、技術・用途・製品・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 世界での大規模な細菌およびウイルスの流行
    • ポイントオブケア診断の需要の増加
    • 薬理ゲノミクスにおける最近の進歩
    • 急速に進化する技術
  • 市場阻害要因
    • 研究開発および経済減速のための限られた予算
    • 非常に複雑な検査センターの必要性
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 技術別
    • In situハイブリダイゼーション
    • チップとマイクロアレイ
    • 質量分析(MS)
    • シーケンス
    • PCR
    • その他の技術
  • 用途別
    • 感染症
    • 腫瘍学
    • 薬理ゲノミクス
    • 微生物学
    • 遺伝病スクリーニング
    • ヒト白血球抗原タイピング
    • 血液スクリーニング
  • 製品
    • 装置
    • 試薬
    • その他
  • エンドユーザー
    • 病院
    • 実験室
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • F. Hoffmann-la Roche Ltd
    • Illumina, Inc.
    • Hologic Corporation
    • Agilent Technologies / Dako
    • Qiagen
    • Myriad Genetics
    • BD (Becton, Dickinson And Company)
    • Abbott Laboratories
    • Cepheid Inc.
    • Genomic Health Inc.

第7章 市場機会および将来動向

目次
Product Code: 47536

Market Overview

The global molecular diagnostics market was valued at USD 7,854.45 million in 2018, and is estimated to be valued at USD 13,340.35 million by 2024, while witnessing a CAGR of 9.23% during the forecast period, 2019-2024. Factors that are responsible for the growth of the market include large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, recent advancements in pharmacogenomics, and rapidly evolving technology.

Molecular diagnostics is considered to be the best method to identify and characterize a microorganism. An effective test must be precise, rapid, and also be able to measure the infectious burden. Better testing quickly identifies the organism's strain and drug susceptibility, thus, reducing the delay in finding the right antibiotic. Technological advancements, like a polymerase chain reaction (PCR), have also made it possible to identify the antimicrobial resistance genes and provide public health information, such as strain characterization by genotyping. The infectious disease segment currently records the highest growth in the molecular diagnostics market.

Scope of the Report

Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, insertions, and others), which may or may not be associated with diseases. Molecular diagnostics has been revolutionized over the past few decades. Currently, it is the driving force behind the transformation in healthcare, thus, leading to innovations in the field of molecular biology. These include next-generation sequencing, microarray technologies, liquid biopsies, early cancer detection, direct-to-consumer testing, and point-of-care assays.

Key Market Trends

Instruments Sub-segment is Expected to Hold the Largest Market Share in the Product Segment

In the product segment of the global molecular diagnostics market, the instruments sub-segment is believed to have the largest market size and is expected to witness a CAGR of 9.13% during the forecast period.

Molecular diagnostics plays a vital role in the assessment of disease prognosis and therapy response, as well as in the detection of minimal residual disease. In the past decade, molecular diagnostics has grown, due to advances in the chemistries and instrumentation, including automation, integration, throughput, and the ability to use the instrumentation in a random-access mode.

Some of the sophisticated instruments used in this market are High-performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), along with real-time PCR, Enzyme-linked ImmunoSorbent Assay (ELISA), RadioImmunoAssay (RIA), lateral flow devices, patient safety syringes, point-of-care testing devices, and others.

North America Dominates the Market and is Expected to do the Same over the Forecast Period

North America currently dominates the molecular diagnostics market and is expected to continue its stronghold for a few more years. The United States accounts for the largest market share in the overall North American molecular diagnostics market. Molecular diagnostics has played a vital role in changing the face of disease diagnostics and assuring speedy detection and accurate care for critically ill patients. The increase in per capita health expenditures, the advancement in healthcare infrastructure, and the increase in the number of infectious diseases and cancer cases in the United States have led to a shift in trend from the traditional diagnostic methods to molecular diagnostics.

In addition, rising technological advancements, increasing entry of new players, and speedy adoption of advanced molecular diagnostics, are helping in the growth of the market in the United States.

Competitive Landscape

The global molecular diagnostics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to small companies are increasing their market presence by introducing new devices with fewer prices. Companies, like Abbott Laboratories, F. Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technology, hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Large Outbreaks of Bacterial And Viral Epidemics in the World
    • 4.2.2 Increasing Demand for Point-of-care Diagnostics
    • 4.2.3 Recent Advancements in Pharmacogenomics
    • 4.2.4 Rapidly Evolving Technology
  • 4.3 Market Restraints
    • 4.3.1 Limited Budgets for R&D and Economic Slowdown
    • 4.3.2 Need for High-complexity Testing Centers
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Technology
    • 5.1.1 In Situ Hybridization
    • 5.1.2 Chips and Microarrays
    • 5.1.3 Mass Spectrometry (MS)
    • 5.1.4 Sequencing
    • 5.1.5 PCR
    • 5.1.6 Other Technologies
  • 5.2 Application
    • 5.2.1 Infectious Disease
    • 5.2.2 Oncology
    • 5.2.3 Pharmacogenomics
    • 5.2.4 Microbiology
    • 5.2.5 Genetic Disease Screening
    • 5.2.6 Human Leukocyte Antigen Typing
    • 5.2.7 Blood Screening
  • 5.3 Product
    • 5.3.1 Instruments
    • 5.3.2 Reagents
    • 5.3.3 Other Products
  • 5.4 End User
    • 5.4.1 Hospitals
    • 5.4.2 Laboratories
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-la Roche Ltd
    • 6.1.2 Illumina, Inc.
    • 6.1.3 Hologic Corporation
    • 6.1.4 Agilent Technologies / Dako
    • 6.1.5 Qiagen
    • 6.1.6 Myriad Genetics
    • 6.1.7 BD (Becton, Dickinson And Company)
    • 6.1.8 Abbott Laboratories
    • 6.1.9 Cepheid Inc.
    • 6.1.10 Genomic Health Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top